| Document |
Document Title |
|
WO/2023/208020A1 |
Disclosed are an intermediate of a polyamine derivative pharmaceutical salt, a preparation method therefor, and use thereof. The intermediate compound has the following structure: (I), which can be used to prepare a polyamine derivative ...
|
|
WO/2023/208170A1 |
Provided are a protease inhibitor, a method for preparing same, and use thereof. The protease inhibitor can be combined with one or more pharmaceutically acceptable excipients or one or more other active ingredients to be used as a PLpro...
|
|
WO/2023/202559A1 |
The application provides a phenyl acrylic compound, and a preparation method and application thereof. The phenyl acrylic compound has a structure as shown in formula (I). The phenyl acrylic compound provided by the present application ca...
|
|
WO/2023/201067A2 |
Embodiments of the present disclosure relate to a chemical entity formed by reaction of components B and C, wherein component C is a moiety comprising one or more amine groups, and component B is a compound of Formula (I): wherein, A is ...
|
|
WO/2023/198484A1 |
The invention relates to an improved process for recovering N,N-Dimethylformamide (DMF) from an aqueous process stream by adjusting the pH, extracting with Chloroform and subsequent distillation/rectification.
|
|
WO/2023/196788A2 |
The present invention provides methods, compositions, and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, and related conditions. The present invention provides co...
|
|
WO/2023/192665A2 |
Disclosed herein are compounds for treating a condition modulated by calcium channel ion activity and pharmaceutical compositions comprising the compounds, wherein the compounds comprise a cyclohexane, a cyclopentane, or a cyclobutane co...
|
|
WO/2023/192814A1 |
The present disclosure encompasses novel benzamide enaminone compounds and pharmaceutically acceptable salts thereof and compositions including such compounds and pharmaceutically acceptable salts. The disclosure further encompasses meth...
|
|
WO/2023/191951A1 |
The present invention relates to novel 5HT receptor modulators, such as compounds of the general Formula (I) and general Formula (II): or a pharmaceutically acceptable salt thereof. Methods of using the compounds include, for example, mo...
|
|
WO/2023/179499A1 |
The present invention relates to the field of gene drug delivery, and particularly to a lipid compound having a glycerol skeleton, a lipid carrier based on the lipid compound, a nucleic acid lipid nanoparticle composition, and a pharmace...
|
|
WO/2023/175526A1 |
The present invention generally relates to a process for preparation of azabicyclo [3.1.0] hexane intermediate of Formula (I), an intermediate for preparation of certain antiviral compounds for example boceprevir and nirmatrelvir. Wherei...
|
|
WO/2023/175615A1 |
The present disclosure provides apoptosis related protein in the TGF-beta signaling pathway (ARTS) mimetic compounds, compositions and uses thereof for treating neoplastic disorders affecting the neural system and/or neural cell in a sub...
|
|
WO/2023/166507A1 |
The present disclosure provides apoptosis related protein in the TGF-beta signaling pathway (ARTS), any fragments thereof, or at least one mimetic compound thereof upregulating p53 levels in a cell. The present disclosure further provide...
|
|
WO/2023/165353A1 |
Disclosed is the use of an H+/OH- switching type multifunctional monomer in emulsion polymerization. The present invention belongs to the fields of the synthesis of multifunctional monomers and emulsion polymerization. In the present inv...
|
|
WO/2023/164201A1 |
A compound which is useful as a STING inhibitor is provided. The present inventors have found aryl alkynamide derivatives having an inhibitory action on STING. The aryl alkynamide derivatives of the present invention have an inhibitory a...
|
|
WO/2023/161940A1 |
The present invention provides ARTS mimetic compounds that act as novel antagonists for XIAP and Bcl-2. Moreover, the novel ARTS mimetic compounds of the invention induce apoptosis in premalignant and malignant cells. The invention thus ...
|
|
WO/2023/155873A1 |
The present application provides a carboxylic acid compound, a method for preparing same, and use thereof in pharmaceutics. Specifically, the present application provides a carboxylic acid compound represented by formula (I), a method fo...
|
|
WO/2023/156605A1 |
The present invention relates to a novel and efficient method for the production of sphingolipids via the N-acylation of lysosphingolipids such as D-eritro-sphingosine or 6-hydroxy D-eritro-sphingosine, analogues thereof, or salts thereo...
|
|
WO/2023/151157A1 |
A chemical intermediate and a preparation method, belonging to the technical field of dye intermediate synthesis. The chemical intermediate provides a new way for preparing anthraquinone dyes and dye intermediates. The preparation method...
|
|
WO/2023/148747A1 |
The present application provides improved processes for preparation of Nirmatrelvir and intermediates thereof. The claimed process is commercially viable, advantageous and provides novel intermediates for the preparation of Nirmatrelvir....
|
|
WO/2023/150290A2 |
Crosslinking agents, TRI-1, TRI-2, and TRI-3, and/or a collagen crosslinking mixture comprising two or more of TRI-1, TRI-2 and TRI-3, are presented, as are the syntheses thereof. The collagen crosslinking effects of the mixture of TRI-1...
|
|
WO/2023/148138A1 |
The present invention relates to compounds which are suitable as hair repair agents or fabric repair agents, to compositions and kits comprising such compounds, to the use of such compounds as hair repair agents or fabric repair agents, ...
|
|
WO/2023/144798A1 |
Certain embodiments of the invention provide ionizable lipids having optimized clearance properties. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising ionizable lipids, methods of making the lipid ...
|
|
WO/2023/143601A1 |
Provided in the present invention are a novel cationic lipid, a lipid nanoparticle and a nucleic acid vaccine. In the present invention, a specific cationic lipid is selected for preparing a lipid nanoparticle mRNA vaccine, which is foun...
|
|
WO/2023/145967A1 |
[Problem] To provide a novel compound that is promising as a probe for nuclear medical testing. [Solution] Provided is a compound represented by general formula (I) or a salt thereof.
|
|
WO/2023/143600A1 |
The present invention provides a novel cationic lipid, a lipid nanoparticle, and a nucleic acid vaccine. According to the present invention, a specific cationic lipid is selected to prepare a lipid nanoparticle mRNA vaccine, and the lipi...
|
|
WO/2023/143591A1 |
The present invention provides a novel cationic lipid, a lipid nanoparticle and a nucleic acid vaccine. It is found that the lipid nanoparticle mRNA vaccine prepared in the present invention by selecting a specific cationic lipid has bet...
|
|
WO/2023/139581A1 |
Compounds represented by Formula I: (I) wherein A, B, W, V, Z, Ra, Rb, n and m are as defined in the instant specification, or by Formula la, lb, III, IV or V, as defined in the instant specification, and uses thereof in modulating an ac...
|
|
WO/2023/132352A1 |
The present invention provides a method that is for producing an amide compound, that comprises obtaining an amide compound by causing a reaction between a carboxylic acid compound and an amine compound in the presence of a condensing ag...
|
|
WO/2023/122842A1 |
The present invention relates to a method for preparing apalutamide, having formula (I). The invention also relates to synthesis intermediaries used in the method for preparing apalutamide, having formula XI [compound XI: N-(6-cyano-5-(t...
|
|
WO/2023/123695A1 |
The present invention belongs to the technical field of drug synthesis, and particularly relates to a dichloroacetic-acid-coupled diphenylethane compound, and a preparation method therefor and the use thereof. The structure of the dichlo...
|
|
WO/2023/124736A1 |
The present invention relates to the technical field of medical materials, and provides an X-ray developable molecule, an X-ray developable embolic microsphere and a preparation method therefor, comprising the following steps: step 1, pr...
|
|
WO/2023/124236A1 |
The present invention relates to the preparation of an antiviral drug, and in particular to an intermediate product for synthesizing Paxlovid and a preparation method. The structures of two intermediate products for synthesizing Paxlovid...
|
|
WO/2023/121970A1 |
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
|
|
WO/2023/121753A1 |
The present disclosure provides enynes, end-functionalized polymers, conjugates, methods of preparation, compositions, kits, and methods of use. The conjugates comprise at least (1) a peptide (e.g., an antibody), protein, nucleoprotein, ...
|
|
WO/2023/118576A1 |
The invention relates to novel, optionally deuterated compounds of Formula (I) and their use as medicament.
|
|
WO/2023/120769A1 |
The present invention provides a method for preparing an amidopolyamine or imidazoline-type asphalt additive, and an asphalt additive composition prepared thereby. An asphalt additive composition according to one embodiment of the presen...
|
|
WO/2023/117928A1 |
The object of the present invention is new precursor compounds and derivatives of N- oxalylglycine as well as the cosmetic use of N-oxalylglycine, its precursors and derivatives in the hair field, and in particular for thickening hair.
|
|
WO/2023/114943A2 |
Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nan...
|
|
WO/2023/114824A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/115002A1 |
The present disclosure relates to compound Formula (I) methods for making the compounds and methods for their use.
|
|
WO/2023/114819A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/114944A1 |
Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R2a, R2b, R3a, R3b, R7, R8, R9, L1, L2, G1, G2, G3, b, and c are as defined herein. Use of the co...
|
|
WO/2023/107920A1 |
The present disclosure relates to ionizable lipidoid compounds comprising an anisamide moiety, and lipid nanoparticles (LNPs) comprising the same. In certain embodiments, the LNP selectively binds to at least one sigma receptor. In certa...
|
|
WO/2023/105516A2 |
The present disclosure relates to a process for preparing a N-substituted acetamide, the process including the steps of: (a) reacting an aniline or derivative thereof with a first amount of a chlorinated acyl chloride in presence of a mi...
|
|
WO/2023/107923A1 |
This invention relates to, among other items, treating non-tuberculosis Mycobacteria-associated disease in a human with epetraborole.
|
|
WO/2023/104017A1 |
The present disclosure provides compounds that can inhibit the type III secretion system (TTSS) to decrease the pathogenesis of gram-negative bacteria. These compounds may have wide applications for treating bacteria diseases caused by g...
|
|
WO/2023/107880A1 |
Disclosed herein are mitofusin inhibitors which are capable of inducing mitochondrial fission, decreasing mitochondrial respiration, TCA metabolism, and inducing mitochondrial outer membrane permeabilization that leads to caspase activat...
|
|
WO/2023/099283A1 |
The present invention is related to a method for purifying crude α-sulfo fatty acid salt obtained by the reaction of fatty acid and sulfur oxides, comprising the following steps: a) diluting the crude α-sulfo fatty acid in a solvent an...
|
|
WO/2023/093560A1 |
The present invention discloses a method for preparing an N-fatty acyl amino acid surfactant by means of high-temperature melting and direct condensation. The method of the present invention comprises: mixing a fatty acid, a catalyst and...
|
